Saudi experts on multiple myeloma (MM) have issued a statement on the advanced treatment of relapsed or refractory (RR) MM, highlighting the need for better options due to the limited availability of CAR-T therapies. CAR-T therapies are approved in the region, but are not suitable for patients with advanced age, comorbidities, rapidly progressing disease, or logistical problems. Bispecific antibodies (BsAbs) represent a promising alternative, especially in the absence of regional clinical evidence. The panel of experts used a modified Delphi method and reached agreement on 30 of 35 statements (86%) in the areas of patient selection, sequencing, dosing, monitoring, and efficacy. BsAbs are recommended for treatment of triple-refractory MM after positive clinical trial results with high response rates, prolonged progression-free survival and overall survival. BsAbs are preferred over CAR-T in patients with rapidly progressive disease due to delays in the production of CAR-T. The document provides a framework for the optimal use of BsAbs in Saudi Arabia.